AU4578893A - Peptides that mimic gp120 hiv epitope - Google Patents
Peptides that mimic gp120 hiv epitopeInfo
- Publication number
- AU4578893A AU4578893A AU45788/93A AU4578893A AU4578893A AU 4578893 A AU4578893 A AU 4578893A AU 45788/93 A AU45788/93 A AU 45788/93A AU 4578893 A AU4578893 A AU 4578893A AU 4578893 A AU4578893 A AU 4578893A
- Authority
- AU
- Australia
- Prior art keywords
- molecule
- peptide
- hiv
- modified
- peptide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 101
- 230000003278 mimic effect Effects 0.000 title claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 title description 6
- 150000001413 amino acids Chemical group 0.000 claims description 43
- 235000001014 amino acid Nutrition 0.000 claims description 39
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 24
- 208000030507 AIDS Diseases 0.000 claims description 16
- 230000002163 immunogen Effects 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 3
- 235000020776 essential amino acid Nutrition 0.000 claims description 3
- 239000003797 essential amino acid Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 46
- 210000002966 serum Anatomy 0.000 description 37
- 208000031886 HIV Infections Diseases 0.000 description 32
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 32
- 241000283973 Oryctolagus cuniculus Species 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 241000725303 Human immunodeficiency virus Species 0.000 description 27
- 108091036078 conserved sequence Proteins 0.000 description 22
- 241000700605 Viruses Species 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 9
- 238000002649 immunization Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102100034349 Integrase Human genes 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000004201 immune sera Anatomy 0.000 description 5
- 229940042743 immune sera Drugs 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DXQOQMCLWWADMU-ACZMJKKPSA-N Asp-Gln-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DXQOQMCLWWADMU-ACZMJKKPSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- YQEHNIKPAOPBNH-DCAQKATOSA-N Cys-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N YQEHNIKPAOPBNH-DCAQKATOSA-N 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 2
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000282537 Mandrillus sphinx Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- ZRSZTKTVPNSUNA-IHRRRGAJSA-N Val-Lys-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(O)=O ZRSZTKTVPNSUNA-IHRRRGAJSA-N 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010090894 prolylleucine Proteins 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- MFGALGYVFGDXIX-UHFFFAOYSA-N 2,3-Dimethylmaleic anhydride Chemical compound CC1=C(C)C(=O)OC1=O MFGALGYVFGDXIX-UHFFFAOYSA-N 0.000 description 1
- KKYFGXDILCPMIT-UHFFFAOYSA-N 3-hydroxy-1,2-dihydro-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)NNC2=C1 KKYFGXDILCPMIT-UHFFFAOYSA-N 0.000 description 1
- HWJNMTWBPYQWKU-UHFFFAOYSA-N 3-hydroxy-2-phenoxypropanoic acid Chemical compound OCC(C(O)=O)OC1=CC=CC=C1 HWJNMTWBPYQWKU-UHFFFAOYSA-N 0.000 description 1
- VIGKUFXFTPWYER-BIIVOSGPSA-N Ala-Cys-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N VIGKUFXFTPWYER-BIIVOSGPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- HLTLEIXYIJDFOY-ZLUOBGJFSA-N Asn-Cys-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O HLTLEIXYIJDFOY-ZLUOBGJFSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 102100025232 Calcium/calmodulin-dependent protein kinase type II subunit beta Human genes 0.000 description 1
- QDFBJJABJKOLTD-FXQIFTODSA-N Cys-Asn-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QDFBJJABJKOLTD-FXQIFTODSA-N 0.000 description 1
- NQSUTVRXXBGVDQ-LKXGYXEUSA-N Cys-Asn-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NQSUTVRXXBGVDQ-LKXGYXEUSA-N 0.000 description 1
- HMWBPUDETPKSSS-DCAQKATOSA-N Cys-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCCN)C(=O)O HMWBPUDETPKSSS-DCAQKATOSA-N 0.000 description 1
- OELDIVRKHTYFNG-WDSKDSINSA-N Cys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CS OELDIVRKHTYFNG-WDSKDSINSA-N 0.000 description 1
- FNXOZWPPOJRBRE-XGEHTFHBSA-N Cys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)N)O FNXOZWPPOJRBRE-XGEHTFHBSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical group OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001077352 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit beta Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- WVUDHMBJNBWZBU-XUXIUFHCSA-N Ile-Lys-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)N WVUDHMBJNBWZBU-XUXIUFHCSA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- VEGLGAOVLFODGC-GUBZILKMSA-N Lys-Glu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VEGLGAOVLFODGC-GUBZILKMSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- JCVOHUKUYSYBAD-DCAQKATOSA-N Lys-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N)C(=O)N[C@@H](CS)C(=O)O JCVOHUKUYSYBAD-DCAQKATOSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- OYTNZCBFDXGQGE-XQXXSGGOSA-N Thr-Gln-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O OYTNZCBFDXGQGE-XQXXSGGOSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- -1 acetamidomethyl Chemical group 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Substances CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Title PEPTIDES THAT MIMIC GP120 HIV EPITOPE.
Field of the Invention
This invention concerns developments relating to human immunodeficiency viruses (HIV).
Background to the Invention
The envelope glycoprotein (env) of human immunodeficiency virus (HIV) is highly variable between independent
isolates (reference 1) and this variation is even more marked between HIV-1 and HIV-2(2). This variation is seen not only between independent isolates, but also for sequential isolates of virus from an individual patient (3, 4). Not surprisingly, similar sequence variation has been observed between the human and simian
immunodeficiency viruses (SIV) and also within SIV even when isolated from the same species of simian (5-7).
Not only is the variation greater in the envelope
glycoprotein than in other gene products of HIV, but even within this one protein the variation is concentrated into specific variable regions (mostly in the surface portion (gp120) generated by the proteolytic maturation of the initial gene product), with other regions being less variable (8, 9). Unfortunately the most variable regions are often also the most immunogenic (10), so that the virus partially evades the host's immune response and
establishes a persistent infection.
This variability presents problems for diagnostic
techniques based upon specific interactions, with separate or mixed reagents usually being employed to test samples for both HIV-1 and HIV-2. This variability also presents problems for any possible vaccine or immune therapy, since any suitable agent will have to give a response towards the many variant virus strains as well as towards HIV-1 and HIV-2.
The present invention is based on the discovery by the inventors of a hitherto unrecognised highly conserved undecapeptide in gp 120 of env, starting from position 122 (on our alignment of HIV-1 env sequences), which is present in HIV-1, HIV-2 and also SIV. This sequence is totally conserved as Lys-Pro-Cys-Val-Lys-Leu-Thr-Pro-Leu-Cys-Val (Seq. Id. No. 1, also referred to as sequence A) in all listed isolates of both types of HIV, including the "highly divergent" HIV-2 isolates D194 and D205 ( 11), and only undergoes conservative changes at the threonine and second valine in all isolates of SIV except in the highly divergent African mandrill isolate (12) wherein threonine and both leucines are mutated.
In this specification amino acids are either identified by their full names, by conventional 3 letter abbreviations or by conventional 1 letter symbols, as listed in Table 1.
Table 2 gives amino acid sequence data for a number of different isolates of HIV-1, HIV-2 and SIV compared with the highly conserved consensus sequence. The consensus sequence is based upon an absolute majority; for
individual isolates a dash indicates agreement with the consensus, otherwise the amino acid is shown.
Comparison of the nucleotide sequences in the gene coding for this peptide also shows a high degree of conservation, although the redundancy of the genetic code allows
slightly wider variation.
Sequence information was taken from the Los Alamos Data
Base.
Earlier reports have shown that the imraunodominant regions of gp120 are largely in the variable loops, particularly V3 (e.g. 10). Limited studies with peptides have included the conserved region we describe (e.g. 13). These
peptides showed very little immunogenicity. This is now thought to be because no precautions were taken to protect the amino acid side chains from modification during conjugation to the carrier protein.
The conserved sequence identified above is referred to in EP 0298633 of Proteus Biotechnology Limited as the
possible basis of a vaccine to promote immunity against at least one strain of HIV. The sequence is stated to have been chosen on the basis of its topographical similarity to at least one other antigenic determinant of the HIV envelope proteins. However, there is no indication in EP 0298633 of an appreciation of the high degree of
conservation of the sequence between different strains of HIV-1, HIV-2 and SIV.
EP 0298633 also discloses linking the C terminal of the conserved sequence identified above to a further sequence chosen in similar manner, and it is stated in this
document that the inessential C terminal dipeptide Cys-Val may possibly be omitted, and that the first Cys residue of the sequence may be cross linked to another Cys residue in the molecule via an intramolecular disulphide bridge.
The present invention is further based on the appreciation that correct presentation of the conserved seqence is very important for eliciting an immune response. It is now known that in its native form the conserved sequence identified above is cross-linked via intramolecular disulphide bridges to a further sequence of gp120
different from that proposed in EP 0298633. This further sequence (sequence B) is also highly conserved within strains of both HIV-1 and HIV-2, with only limited
mutations between the two types. SIV isolates show strong similarities to either HIV-1 (SIVCPZ) or HIV-2 (all other strains of SIV) (Table 3). It is further now appreciated that both cysteine residues of the conserved sequence identified above are involved in respective disulphide bridges in the native confirmation (14), and it is
believed that both cysteine residues are required to elicit a proper immune response, contrary to the statement in EP 0298633 that one of the cysteine residues is
inessential. The strong conservation of this second peptide is fully compatible with it forming an essential structural conformation together with the conserved sequence.
In order to demonstrate this, the present inventors have carried out work using the conserved sequence identified above with both cysteine residues derivatised to
approximate to one half of a disulphide bond, thus
mimicking native presentation. Initial immunogenic studies on this peptide show that the peptide is
immunogenic when presented coupled to an appropriate carrier protein and that the resulting antisera react with native gp 120 in permeabilised cells. Work has been carried out using the conserved sequence identified above linked to a further sequence via disulphide bridges from both cysteine residues of each sequence in appropriate orientation.
Summary of the Invention
In one aspect the present invention provides a molecule comprising a peptide having the amino acid sequence lysine-proline-cysteine-valine-lysine-leucine-threonineproline-leucine-cysteine-valine (Seq. Id. No. 1), wherein each cysteine residue is disulphide bridged to a further cysteine residue or is derivatised to simulate part of a disulphide bond, or functionally equivalent variants of such a peptide which mimic the immunogenic behaviour of an epitope of gp120 of HIV env.
The strict conservation of a peptide sequence within the external envelope protein of HIV, coupled with the near conservation in the related SIV, suggests that the
sequence that is the basis of the invention is essential for the function of the env-protein and hence unlikely to change further in other, as yet uncharacterised, isolates. Searches have shown that the sequence is not present in other proteins in the EMBL Data Base and so it appears to be specific to immunodeficiency viruses. The invention therefore offers a possible fixed sequence that has many possible implications for the design of diagnostic, immunogenic agents, and therapeutic agents, as will be explained below.
As explained above, it is important that each cysteine residue contributes to a respective disulphide bridge (actual or simulated by suitable derivatisation) for the molecule to mimic accurately behaviour of the
corresponding sequence of gp120. This can be achieved by suitable derivatisation of the cysteine residues, e.g. as the S-acetamidomethyl derivative. This can alternatively be achieved by cross-linking the cysteine residues to respective cysteine residues in a further peptide
sequence, which can either be a continuation of the peptide of the invention, spaced with a suitable linker of peptide or other nature, or a separate peptide. One preferred cross-linking arrangement, which is based on the actual cross-linking now known to occur in gp120 is as follows :
Sequence A is the uniquely conserved sequence on which the present invention is based, and Sequence B is based on the sequence of amino acids 219 to 230 of HIV-1 and 210 to 221 of HIV-2, with mutations indicated below in order of frequency. Sequence B is thus fairly conservative
although different sequences may be optimal for HIV-1 and HIV-2 (Table 3).
Desired peptide sequences can be readily synthesised in conventional manner, e.g. using Fmoc techniques.
Alternatively, peptide sequences can be produced by
recombinant DNA techniques in known manner.
A further aspect of the invention thus provides a DNA molecule coding for a peptide molecule in accordance with the invention, preferably incorporated into a suitable expression vector.
It will be apparent that the molecule of the invention, based on the highly conserved sequence, can be modified in a variety of different ways without significantly
affecting the functionally important immunogenic behaviour of the molecule. Possible modifications to the or each peptide sequence include the following:
1) One or more individual amino acids can be substituted by amino acids having comparable properties e.g. as follows:
V substituted by I
T substituted by S
K substituted by R
L substituted by I, V or M
2) One or more of the normal peptide linkages can be substituted by isosteric replacements. Possible
replacement linkages are well known to those skilled in the art of peptide synthesis and are reviewed, for
example, in reference 15. Examples would include: the use of the azapeptide linkage, where the alpha-carbon of the amino acid is replaced by a nitrogen atom (i.e. -NH-NR-CO-); a reduced amide bond, giving a methyl amine (i.e. -NH-CHR-CH2-); thiomethyl groups, with the CO replaced by CH and the NH by S (i.e. -S-CHR-CH2-); replacement of both the NH and CO groups with unsaturated carbon atoms (i.e.
=CH-CHR-CH=); or replacement of the NH group with a methylene (i.e. -CH2-CHR-CO-).
3) One, or both, pairs of disulphide-bridged cysteine residues (i.e. cystine residues) can be substituted by a cystine analogue such as:
4) One or more of the amino acids can be replaced by a "retro-inverso" amino acid, i.e. a bifunctional amine having a functional group corresponding to an amino acid, as discussed in WO91/13909.
5) One or more non-essential amino acids can be
deleted.
6) One or more additional amino acids not significantly affecting function can be included.
7) Structural analogs mimicking the 3-dimensional structure of the peptide can be used in place of the peptide.
It has been shown that a molecule in accordance with the invention can elicit an immune response. One possible use of the molecule is therefore as the basis of a potential vaccine against AIDS and AIDS related conditions.
In a further aspect the invention thus provides a vaccine against AIDS and AIDS related conditions, comprising a molecule in accordance with the invention.
For this purpose, the molecule of the invention may optionally be linked to a carrier molecule, possibly via chemical groups of amino acids of the conserved sequence or via additional amino acids added at the C- or N-terminus. Many suitable linkages are known, e.g. using the side chains of Tyr residues. Suitable carriers include, e.g., keyhole limpet hemocyanin (KLH), serum albumin, purified protein derivative of tuberculin (PPD), ovalbumin, non-protein carriers and many others. It is thought the lysine residues in the conserved sequence may be of importance in the molecule of the invention, and for this reason the epsilon-amino groups of lysine residues are preferably protected in known manner during a
conjugation reaction to link a carrier, to prevent
unwanted reaction, with the groups being subsequently regenerated before use of the conjugate.
The molecule of the invention may alternatively be
presented as a possible live vaccine, e.g. as part of the coat of a genetically modified virus such as polio or vaccinia.
The vaccine of the invention may be administered in conventional manner, e.g. by injection, orally etc., with or without use of conventional adjuvants such as Freund's
complete or incomplete adjuvant or aluminium hydroxide, and with or without other immunopotentiating agents.
Diluents suitable for use in formulating the vaccine for administration are also well known, including distilled water, phosphate-buffered saline, and buffer solutions such as citrate buffer.
Molecules in accordance with the invention may further find use in the treatment (prophylactic or curative) of AIDS and related conditions, by acting either to displace the binding of the HIV virus to human or animal cells or by disturbing the 3-dimensional organisation of the virus.
A further aspect of the invention thus provides a method for the prophylaxis or treatment of AIDS or related conditions, comprising administering an effective amount of a molecule in accordance with the invention.
In a further aspect, the invention provides a
pharmaceutical composition containing, as an active ingredient, a molecule in accordance with the invention, possibly in association with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients.
The invention also provides use of a molecule in
accordance with the invention for the preparation of a medicament for the therapy or prophylactic treatment of AIDS or related conditions.
Molecules which bind to the conserved sequence on which the invention is based, particularly antibodies, antibody-related molecules and structural analogs thereof, are also of possible use as agents in the treatment and diagnosis
of AIDS and related conditions.
In a further aspect the invention thus provides a molecule that binds to the conserved sequence that is the basis of the invention, particularly an antibody, an antigen binding site of an antibody or a structural analog
thereof.
Techniques for making antibodies (monoclonal and
polyclonal) are well known to those skilled in the art.
Variants of antibodies (including an antigen binding site), such as chimeric antibodies, humanised antibodies, veneered antibodies, and engineered antibodies generally are included within the scope of the invention.
Techniques for the production of such variants are also well known to those skilled in the art.
With a knowledge of the 3-dimensional structure of the conserved sequence in gp 120, it is possible to design and construct synthetic molecules that will bind to the sequence. Suitable techniques for this purpose are disclosed e.g. in references 16 and 17, which involve the use of computer-modelling to design potential inhibitors to renin.
Antibodies and other molecules which bind to the conserved sequence on which the invention is based can be used for therapeutic (prophylactic and curative) and diagnostic purposes in a number of different ways, including the following:-
1) For passive immunisation by suitable administration of antibodies, preferably humanised antibodies to patients.
2) To activate complement or mediate antibody dependent cellular cytotoxicity (ADCC) by use of antibodies of suitable subclass or isotype (possibly obtained by
appropriate antibody engineering) to be capable of
performing the desired function.
3) For targetted delivery of toxins or other agents, e.g. by use of immunotoxins comprising conjugates of antibody and a cytotoxic moiety, for binding directly or indirectly to the target conserved sequence of gp 120.
4) For targetted delivery of highly immunogenic materials to the surface of HIV-infected cells, leading to possible ablation of such cells by either the humoral or cellular immune system of the host.
5) For detection of HIV, e.g. using a variety of
immunoassay techniques.
Techniques for performing all of the above are well known to those skilled in the art.
In another aspect the invention thus covers use of a molecule which binds to the conserved sequence of the invention for therapeutic or diagnostic purposes.
The invention also includes within its scope methods and kits for detecting HIV, antibodies against HIV or
infection with HIV using molecules in accordance with the invention.
The invention will be further described, by way of
illustration, in the following examples. The first
example concerns immunological studies on a peptide incorporating the highly conserved seqence, which show that the peptide is immunogenic, as presented, and that the antisera react with native gp 120 in infected cells. The example refers to Figures 1 to 4 of the accompanying drawings, in which:
Figure 1 is a series of photographs showing
immunofluorescence of cells, some expressing gp 120 from
HIV-1, treated with sera obtained from a rabbit before and after treatment with the peptide, with the serum treated with peptide before application to the cells in some cases;
Figure 2 is a series of photographs showing
immunofluorescence of cells, either uninfected or infected with different isolates of HIV-1, treated with sera obtained from a rabbit before and after treatment with the peptide;
Figure 3 is a series of photographs showing
immunofluorescence of cells, uninfected or infected, treated with sera obtained from two different rabbits before and after treatment with the peptide; and
Figure 4 is a series of photographs showing
immunofluorescence of cells, either uninfected or infected with HIV-2, treated with sera obtained from a rabbit before and after treatment with the peptide.
The second example concerns immunological studies on a peptide incorporating the highly conserved sequence A disulphide-bridged in an antiparallel fashion to the moderately conserved sequence B, which show that the
peptide is immunogenic, as presented, and that the
antiserum reacts with HIV-1 to neutralise its infectivity. The example refers to Figure 5 of the accompanying
drawings in which:
Figure 5 is a graph of virus present in the supernatant fluid above tissue culture cells, measured by the activity of viral reverse transcriptase in incorporating 3H-dTTP, at various times after attempted infection with virus (50
TC1D50) treated for 60 minutes, at 37°C, with the
indicated serum (or phosphate buffered saline, PBS) diluted 1:20 with RPMI/10%FCS.
Examples
Analysis of HIV envelope glycoprotein sequences for conservation
HIV and SIV sequences used for the analysis were from the Los Alamos Data Base. Sequence comparisons were performed on a VAX 8600 computer, using HOMED, Version 3.30, from P A Stockwell, Otago University, Dunedin, New Zealand.
Alignment of the sequences of the envelope glycoprotein sequences of HIV-1 and HIV-2 isolates showed a number of regions with varying degrees of conservation. However most of these were unconserved when comparison was also made to SIV sequences and only a single region of
significant size was still conserved. This occurs in gp 120, immediately before the first hypervariable (V1) loop (9), and the conservation is shown in Table 2. The undecapeptide is absolutely conserved in all isolates of HIV and the changes in SIV are highly conservative, with only changes of T to S and V to I in most isolates (and L
to I, T to N and L to Y in the, otherwise, highly
divergent African mandrill isolate GB1).
The sequence of 11 amino acids appears to be unique to HIV and SIV, with no matches of more than 5 contiguous
residues being found on searching the EMBO and SwissProt sequence data bases (or 6 residues, allowing gaps). The restricted sequence variation of this region of the otherwise highly variable gp 120 suggests that it might be essential for HIV viability and hence not be able to vary significantly and yet maintain infectious progeny
virions.
Alignment of the sequences also showed a high degree of conservation of a second region, immediately after the second hypervariable (V2) loop (9) and disulphide-bridged to both cysteine residues in the first, uniquely conserved region (14), and the conservation is shown in Table 3. The conservation is greatest between the cysteine residues forming the disulphide bridges and each HIV Type is mutated only very conservatively, with the SIV isolates resembling one or other HIV Type. This further suggests that the antiparallel cross-linked peptides form a
structure in gp 120 essential for viability of the virus.
Example 1
Based on this analysis, experiments were carried out using a synthetic peptide based on the highly conserved sequence of the invention.
All chemicals were of analytical grade and were used without further purification, unless otherwise mentioned.
Peptide Synthesis
A peptide having the sequence KPCVKLTPLCVTLY (Seq. Id. No.4) was synthesised by Fmoc continuous flow solid phase synthesis using an automatic synthesiser (LKB Biolynx). Fmoc amino acid pentafluorophenyl esters were used as acylating species throughout, except for Thr where the ester of 2,3-dihydro-3-hydroxy-4-oxo-benzotriazine was preferred. Kieselguhr supported polydimethyl-acrylamide functionalised with the hydroxymethylphenoxy acetic acid linkage and norleucine as internal reference amino acid (18,19) was used as solid support.
The peptide was cleaved from the resin using
trifluoroacetic acid/phenol/triethylsilane (23ml/1g/1ml for 500mg of peptide-resin assembly) which effected simultaneous cleavage of the tert-butyl based side chain protecting groups except for the acid stable Acm
(acetamidomethyl) on the side chain of Cys. The resin was removed by filtration and washed with a little neat trifluoroacetic acid (TFA). The solvent was removed from the combined TFA filtrates by rotary evaporation under reduced pressure. The oily residue was dissolved in 0.1% aq. TFA (20ml) and extracted with diethyl ether (5 × 20ml) and the solvent removed from the combined aqueous phases by freeze drying to yield a white powder (20.9 umols, 76% yield).
The peptide was analysed by HPLC after synthesis and found to be at least 98% pure and was therefore used, without further purification, for coupling to KLH for immunisation of rabbits.
Antiserum production
The peptide was coupled, in about 30-fold molar excess, to KLH, essentially by the protocol of Bassiri and Utiger (20) as modified by Kiberstis et al. (21). Since we were particularly concerned to present the peptide in a
condition as near to that in the native protein as
possible, the Cys residues were left as the S-acetamidomethyl derivative, which was chosen to
approximate to one half of a disulphide bond, and the epsilon-amino groups of the Lys residues were reversibly protected during the coupling reaction, which would otherwise have converted them to hydroxyl groups, by modification with 2,3-dimethylmaleic anhydride (10-fold molar excess) at pH 9.0, prior to coupling, with
subsequent unblocking at pH 6.5, 20ºC, for 8h (22).
Three New Zealand white rabbits (known as Ping, Pong and Pang) (conventionally bred from Rosemeal Rabbits Ltd., UK) were immunised with the equivalent of 0.6mg peptide in Freunds complete adjuvant, by multiple subcutaneous injections and subsequently given 2 boosts subcutaneously with the equivalent of 0.3mg peptide in incomplete Freunds adjuvant. Preimmune and post-immunisation blood samples were taken, together with the final immune blood, and sera prepared by allowing the samples to clot at room
temperature.
Immune responses were monitored by ELISA against the peptide bound to wells of microtitre plates, which were subseqently blocked with bovine serum albumin. Horse radish peroxidase-conjugated goat anti-rabbit antibody ( DAKO Ltd.) was used as the second antibody and 1,2-phenylenediamine, dihydrochloride (DAKO Ltd.) as the substrate.
ELISA of the rabit preimmune sera and also sera after immunisation showed that all 3 rabbits developed a
response to the peptide as an immunogen, when presented coupled to keyhole limpet hemocyanin (Table 4). The final bleeds give enhancements (greater than or equal to 4-fold compared to preimmune serum) at dilutions of 1:6400 or 1:3200, suggesting that the peptide was immunogenic when presented as the conjugate on KLH.
Immunofluorescence study of binding of antisera to HIV-infected cells
Binding of antibodies in the rabbit sera to native gp 120 was assayed using confocal immunofluorescent microscopy (23) with the Bio-Rad MRC 600 confocal microscope, with fluorescein isothiocyanate (FΙTC)-labelled goat anti-rabbit IgG (Sigma Chemical Company), as the second
antibody to show the rabbit antibody. Positive control rabbit antiserum against intact gρ120 was a kind gift of Dr Rod Daniels of the National Institute for Medical
Research, London. The test cells were the human T-lymphoblastoid cell line, C8166, which is non-productively infected with human T-cell lymphotropic virus Type-1 (24). These were grown in RPMI/10% fetal calf serum and infected with HIV-1 BRU (25), HIV-1 SF2 (26), or else uninfected as a control. Cells (10 in 15ul) were transferred to the wells of poly-L-lysine treated microscope slides and allowed to bind for 30 min at room temperature, before being fixed with 4% glutaraldehyde then treated with 0.1% Triton X100 to permeabilise the plasma membranes.
Antisera at appropriate dilutions in PBS were added and allowed to bind for 60min at room temperature before the cells were washed. Fluorescein-labelled second antibody
was then added (at the dilution recommended by the
supplier) and allowed to bind for 60min before washing in PBS. The slides were then examined in the confocal microscope, to detect antibody binding, and appropriate specimens photographed.
Binding of immune sera to cells expressing gp 120 of HIV- 1IIIB was determined, using both preimmune sera and also uninfected cells as controls. Typical fields for one rabbit (Pang) are shown in Figure 1. In the upper panel of this Figure, cells were either not expressing gp 120 (a,b and f) or expressing (all other photographs) and were treated with either preimmune serum (a and e) or immune serum (all other photographs). In the lower panel of this Figure, all cells were expressing gp 120 and were treated with immune serum from one rabbit (Pang) either without peptide (i and m) or after incubation with peptide A (j and n), or from another rabbit (Ping) again without peptide (k and o) or after incubation with peptide A (l and p).
Figure 1 shows major binding only with the immune sera and gp 120 expressing cells, while low binding is seen for serum onto non-expressing cells or for preimmune serum onto infected cells. The distribution of binding of immune serum to the gp 120 expressing cells is very similar to that seen for control serum, from a rabbit immunised with gp 120, binding to expresssing, but not non-expressing, cells. Moreover, the binding of immune serum to infected cells is blocked by the peptide, indicating that it is to a specific site on the gp 120.
Binding of the immune sera to HIV-derived material in
infected cells was determined, using both preimmune sera and also uninfected cells as controls. Typical fields for one rabbit (Ping), with HIV-BRU, are shown in Figure 2. In this Figure, cells were either uninfected (a,b,e and f) or infected with HIV-1 BRU (c and d) or SF2 (g and h), while the serum was either preimmune (a, c, e and g) or the immune (b, d, f and h). Bar represents 25 um.
Figure 2 shows major binding only with the immune serum and infected cells, while low binding is seen for either serum onto uninfected cells or for preimmune serum on infected cells. The distribution of the binding of immune serum to the infected cells is similar to that seen for control serum, from a rabbit immunised with gp 120, binding to infected cells, but not uninfected cells.
Repetition of these experiments with cells infected with HIV-1 SF 2 showed very similar results (Figure 1 g and h), confirming that the reaction is independent of the HIV strain employed.
Results of similar tests with sera from the 2 further rabbits (Pong and Pang) and HIV-1 SF2 are shown in Figure 3. Figure 3a shows results using either preimmune serum (upper left) or immune serum (remaining pictures) from Pong with infected cells in each case, and Figure 3b shows results using immune serum from Pang, with either
uninfected cells (upper left) or infected cells (remaining pictures). Bar represents 25 um.
Similar binding was seen with the sera from the rabbit Pong to cells infected with HIV-1 BRU or SF2 (Figure 3a). The third rabbit (Pang) again showed binding of its hyperimmune serum, but in this case the preimmune serum also bound to HIV-1 BRU-infected cells and so no
conclusion can be drawn about the response. However, cells infected with HIV-1 SF 2 showed results very similar to those with the other rabbits, with both the preimmune and immune sera (Figure 3b) and, with this strain of virus, the preimmune serum did not bind and so binding could be shown to result from immunisation.
Figure 4 shows binding of sera from one rabbit (Pong) to cells infected with HIV-2. The cells were either
uninfected (a and b) or infected with HIV-2 CAM2, and were treated with either preimmune (a and c) or immune serum (b and d). Again binding is seen only with the immune serum onto infected cells.
These results demonstrate that the highly conserved sequence of gp 120 in the form presented, i.e. coupled to keyhole limpet hemocyanin and with the cysteine residues in a configuration mimicking disulphide bridges and the epsilon-amino groups of the lysine residues maintained, gave a good immune response in the 3 rabbits tested. The resulting antisera bind to native gp 120 from a number of strains of HIV-1, and to HIV-2.
This extent of conservation, coupled with the surface accessibility of the epitope, suggests that this peptide may have some functional role in the native protein. One possible role could be in binding to a receptor additional to the well characterised CD4.
Example 2
Further experiments have been carried out using a peptide including the conserved sequence of the invention (A chain peptide) cross linked by disulphide bridges to a further
peptide (B chain peptide) based on the cross linked sequences naturally occurring in gp 120.
The sequences of A chain peptide and B chain peptide (with cross-linking indicated) are as follows:
Further experiments were carried out using a disulphide-bridged peptide based upon the sequences A and B of the invention.
Peptide Synthesis
Peptides having the sequences DQSLKPCVKLTPLCVTLY (A chain) (Seq. Id.No.6) and LINCNRSAIKESCPKVSF (B chain)
(Seq. Id.No.5) were synthesised as described in Example 1, but with the cysteine residues protected by Acm on
cysteine 7 and Trityl on cysteine 14 of the A chain, and by Trityl on cysteine 4 and Acm on cysteine 13 of the B chain. Trityl groups were removed from each peptide by acidolysis and the resulting cysteine in the A chain then reacted with 2-dipyridyl disulphide and gel filtered to remove excess reagent. The activated peptide was then reacted with 1.5-fold excess of B chain and the singly disulphide-bridged peptide purified on Whatman CM52 cation exchange resin.
The second disulphide-bridge was then formed specifically by reaction with 10 equivalents of I2 in methanol. The
peptide was finally purified by gel filtration.
Antiserum Production
The disulphide-bridged peptide was coupled to KLH exactly as described in Example 1, with the same protection for the lysine residues. Two rabbits (Tristan and König
Marke) were immunised by subcutaneous injection of the KLH conjugate in Freunds complete adjuvant, followed by a single boost with the same conjugate in Freunds incomplete adjuvant. Subsequent boosts were with peptide alone in Freunds incomplete adjuvant.
Immune responses were analysed by ELISA against
biotinylated peptide bound to streptavidin coated wells of microtitre plates. The development reagents were the same as those in Example 1.
ELISA of the rabbit preimmune sera and also sera after immunisation showed that both rabbits developed a response to the peptide as immunogen, when presented as described (Table 5). The final bleeds gave enhancements (greater than 10-fold compared to the preimmune sera) at ddilutions of 1:16000.
Study of Virus Neutralisation by Antisera
Samples (50 tissue culture infective doses (TCID50)) of HIV-1BRU were incubated with 1:20 dilutions of either preimmune or immune sera from one rabbit (Tristan), or as controls with PBS or serum from a rabbit immunised with gp 120 from HIV-1BRU, for 60 minutes at 37°C. The treated virus was then used to infect C8166 tissue culture cells and the course of infection followed by standard methods,
measuring the virus present in the supernatant over the cells by the reverse transcriptase activity released by Triton X100, following the incorporation of 3H-dTTP with poly-A as template and oligo-dT as primer.
Figure 5 shows that the virus in the supernatant rose about 1000 fold between days 7 and 12 after infection with the virus incubated with the control of PBS, while
incubation of the virus with antiserum against gp 120 prevented any sign of infection. The preimmune serum did not affect the infection, but the immune serum was as effective in preventing infection as the anti-gp 120 control serum.
Immunisation with the disulphide-bridged peptide of the invention, by the method described above, therefore led to the presence of antibodies in the serum which would neutralise the virus infectivity. Moreover the sequence of the B chain in the immunogen is not identical to that of the equivalent peptide in HIV-1 RU and yet
neutralisation is found, suggesting that the overall peptide will lead to antibodies reacting with variants of HIV-1 or HIV-2, although better rection with the specific HIV Types might be obtained with one peptide species for each as discussed above.
Table 1
Abbreviations for amino acids
Amino acid Three-letter One-letter abbreviation symbol
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamine Gln Q
Glutamic acid Glu E
Glycine Gly G
Histidine His H
Isoleucine Ile I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
Table 2
10 20
Consensus DQSLKPCVKLTPLCVTLNC-D (Seq. Id. No. 7)
1 HIV-1 : Z 6 - - - - - - - - - - - - - - - - - - - -T-
2 HIV-1: HXB 2 - - - - - - - - - - - - - - - S-K-T-
3 HIV-1: ELI - - - - - - - - - - - - - - - - - - - -S-
4 HIV-1: HAN - - - - - - - - - - - - - - - - - - K -T-
5 HIV-1: CDC 451 - - - - - - - - - - - - - - - - - - - -T-
6 HIV-1: BRVA - - - - - - - - - - - - - - - - - - - -H-
7 HIV-1: JFL - - - - - - - - - - - - - - - - - - - -IN
8 HIV-1: BRU - - - - - - - - - - - - - - - -S-K-T-
9 HIV-1: JH 3 - - - - - - - - - - - - - - - - - - - -I-
10 HIV-1: JR-CSF - - - - - - - - - - - - - - - - - - --K-
11 HIV-1: JR-FL - - - - - - - - - - - - - - - - - - - -K-
12 HIV-1: ALA 1 - - - - - - - - - - - - - - - - - -H-I-
13 HIV-1: JY 1 - -N- - - - - - - - - - - - - - - - -TN
14 HIV-1: MAL - - - - - - - - - - - - - - - - - - - -TN
15 HIV-1: MFA - - - - - - - - - - - - - - - -N-K-T-
16 HIV-1: MN - - - - - - - - - - - - - - - - - - - -T-
17 HIV-1: NDK - - - - - - - - - - - - - - - - - - - -T-
18 HIV-1: NY 5 - - - - - - - - - - - - - - - - -T-
19 HIV-1: OYI - - - - - - - - - - - - - - - - - -D-T-
20 HIV-1: RF - - - - - - - - - - - - - - - - - - - -T-
21 HIV-1: SC - - - - - - - - - - - - - - - - - -TN
22 KIV-1: SF 162 - - - - - - - - - - - - - - - -H-TN
23 HIV-1: SF 2 - - - - - - - - - - - - - - - - - - -T-
24 HIV-1: SF 33 - - - - - - - - - - - - - - - - - - -T-
25 HIV-1: WMJ 2 - - - - - - - - - - - - - - - - - - -I-
26 HIV-1: Z2 Z6 - - - - - - - - - - - - - - - - - I-
27 HIV-1: Z 321 - - - - - - - - - - - - - - - - -S-HN
28 HIV-2: ST ET-I - - - - - - - - - - -AMR-NS
29 HIV-2: GH 1 ET-I - - - - - - - - - - -AMS-NS
30 HIV-2: ROD ET-I - - - - - - - - - - -AMK-SS
31 HIV-2: BEN ET-I - - - - - - - - - - -AM--SR
32 HIV-2: ISY ET-I - - - - - - - - - - - M--NA
33 HIV-2: NIH Z ET-I - - - - - - - - - - -AM- -TR
34 HIV-2: D 194 ET-I - - - - - - - - - - -AM- -NI
35 HIV-2: D 205 ET-I - - - - - - - - - - -AM--SK
36 SIV: CPZ Q-SK
37 SIV: MNE ET-I - - - - - - - - - -I-MK-NK
38 SIV: SMM-PBJ ET- I - - - - - - - - - -I-MR-NK
39 SIV: SMM-H4 ET-I - - - - - - - - - -I -AMR-NK (IAMR is Seq. Id. No. 8)
40 SIV: MM 239 ET-I - - - - - -S - - -I-MR-NK
41 SIV: MM 251 ET-I - - - - - -S - - -I-MR-NK
42 SIV: MM 142 ET-I - - - - - -S- - -I-MR-NK
43 SIV: AGM 3 E-T- - - - - - -S- - -IKMS-VE (IKMS is Seq. Id. No. 9)
44 SIV: AGM 155 E-T S- --IKM- -VE
45 SIV: TYO-1 E-TM S- - -IKM- -VE
46 SIV: MN-DGB1 -TII - - - - -IN-Y--KMQ-QE
Table 3
10 20
Consensus LI-CNTSVITQACPKVSF (Sea. Id. No. 10),
1 HIV-1 : Z 6 - -N - - - - A - - - - - - - - - -
2 HIV-1 : HXB 2 -TS - - - - - - - - - - - - - - -
3 HIV-1: ELI - - N - - - - A - - - - - - - - - -
4 HIV-1: HAN - - H- - R - - - - - - - - - - - -
5 HIV-1: CDC 451 - - N - - - - - - - - - - - - - - -
6 HIV- 1 : BRVA - - S - - - - - - - - - - - - - T -
7 HIV-1: JFL - -N - - - -T - - - - - - - - - -
8 HIV-1: BRU -TS - - - - - - - - - - - - - - -
9 HIV-1: JH 3 - - S - - - - - - - - - - - - I - -
10 HIV-1: JR-CSF - - S - - - - - - - - - - - - - - -
11 HIV-1: JR-FL - - S - D - - - - - - - - - - I - -
12 HIV-1: ALA 1 - - S - - - - - - - - - - - - - - -
13 HIV-1: JY 1 - -N - - - -A - - - - - - - -T-
14 HIV-1: MAL - -N - - - - - - - - - - - - -T-
15 HIV-1: MFA - - S - - - - - - - - - - - - - - -
16 HIV-1: MN - - S - - - - - - - - - - - -I - -
17 HIV-1: NDK - -N-D - -T - - - - - - - I - -
18 HIV-1: NY 5 - - N - D - - - - - - - - - - - - -
19 HIV-1: OYI - - H - - - -T - - - - - - -I- -
20 HIV-1: RF - -H- -S - - - - - - - - - - - -
21 HIV-1: SC - - N - - - - - - - - - - - - - - -
22 HIV-1: SF 162 - - N - - - - - - - - - - - - - - -
23 HIV-1: SF 2 - -H- -R - - - - - - - - - - - -
24 HIV-1: SF 33 - -H- -S - - - - -T - - - - - -
25 HIV-1: WMJ 2 - -N - - - - - - - - - - - - - - -
26 HIV-1: Z2 Z6 - -N - - - -A - - - - - - - - - -
27 HIV-1: Z 321 - -N - - - -A - - - - - - - - - -
28 HIV-2: ST MNH - - - - - - -ES-D-HYW
29 HIV-2: GH 1 MNH - - - - - - -ES-D-HYW
30 HIV-2: ROD MNH - - - - - - -ES-D-HYW
31 HIV-2: BEN MRH - - - - I -KES-D-HYW
32 HIV-2: ISY MNH - - - - - - -ES-D-HYW
33 HIV-2: NIH Z MNH - - - - - - -ES-D-HYW
34 HIV-2: D 194 MRH - - - - - -KES-D-HYW
35 SIV : CPZ I -N - - -TAH - - - - - - T - -
36 SIV: MNE MNH - - - - - -QES-D-HYW
37 SIV: SMM-PBJ MNH - - - - - -QES-D-HYW
38 SIV: SMM-H4 MHH - - - - - -QES-D-HYW
39 SIV: MM 239 MNH - - - - - -QES-D-HYW
40 SIV MM 251 MNH - - - - - -QES-D-HYW
41 SIV: MM 142 MNH - - - - - -QEC-D-DYW
42 SIV AGM 3 M-H- -D- - -KE- - D -TYW
43 SIV AGM 155 M-H- -D- - -KE- -D-TYW
44 SIV TY0-1 M-H- -D- - -KE- -D-TYW
45 SIV MN-DGB1 MNH- -E- -N-ED-Q-GLL
Tab le 4. ELISA reactivities of sera from rabbits used for immunisation studies.
Serum No peptide added Ping Pang Pong
dilution to well Preimmune Immune serum Preimmune Immune serum Preimmune Immune serum
1 :3200 0.045 0.029 0.354 0.104 0.337 0.130 0.566
1 :6400 0.051 0.034 0.183 0.052 0.210 0.089 0.363
Table 5. ELISA reactivities of sera from rabbits immunised with HB-AIDS2.
Serum No peptide added Tristan König Marke
dilution to well Preimmune Immune serum Preimmu Immune serum
1:2000 0.083 0.056 4.000 0.074 3.889
1:4000 0.076 0.059 4.000 0.067 2.556
1:8000 0.070 0.060 4.000 0.063 1.467
1:16000 0.083 0.081 2.817 0.077 0.880
References
1. Ratner, L, Gallo, R C & Wong-Staal, F (1985) Nature (Lond.) 3 13, 636-637.
2. Clavel, F, Guyader, M, Guetard, D, Salle, M,
Montagnier, L & Alizon, M (1986) Nature (Lond.) 324, 691- 695.
3. Hahn, B H, Shaw, G M, Taylor, M E, Redfield, R R, Markham, P D, Salahuddin, S Z, Wong-Staal, F, Gallo, R C, Parks, E S & Parks, W P (1986) Science (Wash.) 232, 1548-1553.
4. Saag, M S, Hahn, B H, Gibbons, J, Li, Y, Parks, E S, Parks, W P & Shaw, G M (1988) Nature (Lond.) 334, 440-444.
5. Daniel, M D, Letvin, N L, King, N W, Kannagi, M, Sehgal, P K, Hunt, R D, Kanki, P J, Essex, M & Desrosiers, C (1985) Science (Wash.) 228, 1201-1204.
6. Franchini, G, Gurgo, C, Guo, H-G, Gallo, R C,
Collati, E, Fargnoli, K A, Hall, L F, Wong-Staal, F & Reitz, M S J (1987) Nature (Lond.) 328, 539-543.
7. Chakrabarti, L, Guyader, M, Alizon, M, Daniel, M D, DeRosiers, R C, Tiollais, P & Sonigo, P (1987) Nature (Lond.) 328, 543-547.
8. Starcich, B R, Hahn, B H, Shaw, G M, McNeely, P D, Modrow, S, Wolf, H, Parks, E S, Parks, W P, Josephs, S F, Gallo, R C & Wong-Staal, F (1986) Cell 45, 637-648.
9. Modrow, S, Hahn, B H, Shaw, G M, Gallo, R C, Wong-Staal, F & Wolf, H (1987) J Virol. 61, 570-578.
10. Rusche, J R, Javaherian, K, McDanal, C, Petro, J, Lynn, D L, Grimaila, R, Langlois, A, Gallo, R C, Arthur, L O, Fischinger, P J, Bolognesi, D P, Putney, S D &
Matthews, T J (1988) Proc. Nat. Acad. Sci. USA 85, 3198-3202.
11. Kuhnel, H, von Briesen, H, Dietrich, U, Adamski, M, Mix, D, Biesert, L, Kreutz, R, Immelmann, A, Henco, K, Meichsner, C, Andreesen, R, Gelderblom, H & Rubsamen-Waigmann, H (1989) Proc. Natl. Acad. Sci. USA 86, 2383-2387.
12. Tsujimoto, H, Hasegawa, A, Maki, N, Fukasawa, M, Miura, T, Speidel, S, Cooper, R W, Moriyama, E N,
Gojobori, T & Hayami, M (1989) Nature (Lond.) 341, 539-541.
13. Davis, D, Stephens, D M, Willers, C - Lachmann, P J (1990) J Gen. Virol. 7 1 , 2889-2898.
14. Leonard, C K, Spellman, M W, Riddle, L, Harris, R J, Thomas, J N and Gregory, T J (1990). J. Biol. Chem., 265, 10373-10382.
15. Davies, J S (1984) in Spec. Periodical Reps., Amino-Acids Peptides and Proteins, Roy. Chem. Soc. London.
16. Blundell, T, Sibanda, B L and Pearl, L (1983) Nature (Lond.), 304 , 273-275.
17. Sibanda, B L, Hemmings, A M and Blundell, T L (1985)
in "Aspartic Proteinases Their Inhib.", Proc FEBS Adv. Course 1984, pp 339-349. Ed. Kostka, V Publ. by de Gruyter, Berlin.
18. Atherton, E & Sheppard, R C (1989) "Solid Phase Peptide Synthesis: A practical approach." (Oxford
University Press, Oxford).
19. Dryland, A & Sheppard, R C (1988) Tetrahedron 44, 859.
20. Bassiri, R M & Utiger, R D (1972) Endocrinology 90, 722-727.
21. Kiberstis, P A, Pessi, A, Atherton, E, Jackson, R, Hunter, T & Zimmern, D (1983) FEBS Lett. 164, 355-360
22. Butler, P J G & Hartley, B S (1972) in "Methods in Ezymology" (ed. C W Hirs and S N Timasheff), Vol. 25, pp 191-199 (Academic Press, New York and London).
23. White, J G, Amos, W B & Fordham, M (1987) J. Cell Biol. 105, 41-48.
24. Salahuddin, S Z, Markham, PD, Wong-Staal, F,
Franchini, G, Kalyanaraman, V S & Gallo, R C (1983)
Virology 129, 51-64.
25. Wain-Hobson, S, Sonigo, P, Danos, 0, Cole, S &
Alizon, M (1985) Cell 40, 9-17.
26. Sanchez-Pescadoe, R, Power, M D, Barr, P J, Steimer, K S, Stempien, M M, Brown-Shimer, S L, Gee, W W, Renard,
A, Randolph, A, Levy, J A, Dina, D & Luciw, P A (1985) Science (Wash.) 227, 484-492.
S EQUENCE LISTING (1) GENERAL INFORMATION:
(i) APPLICANT:
(A ) NAME : Medical Research Council
(B) STREET: 20 Park Crescent
(C) CITY: London
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP) : WIN 4AL
(G) TELEPHONE : (071) 636 5422
(H) TELEFAX: (071) 323 1331
(A) NAME: Butler, Peter J. G.
(B) STREET: 2 Heron's Close
(C) CITY: Cambridge
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): CB2 4NS
(A) NAME: Hacking, Graeme N. V.
(B) STREET: Selwyn College
(C) CITY: Cambridge
(E) COUNTRY: United Kingdom
(F) POSTAL CODE (ZIP): CB3 9DQ
(ii) TITLE OF INVENTION: Developments relating to human immunodeficiency viruses
(iii) NUMBER OF SEQUENCES: 10
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: FatentIn Release #1.0, Version #1.25 (2) INFORMATION FOR SEQ ID NO: 1:
(i ) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEONESS : single
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Lys Pro Sys Val Lys Leu Thr Pro Leu Cys Val 1 5 10
(2) INFORMATION FOR SEQ ID NO: 2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(D ) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Asn Cys Asn Thr Ser Val Ile Thr Gln Ala Cys Pro 1 5 10
( 2 ) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 ammo acids
(B) TYPE: amino acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
Asp Ser Thr Ala
1
(2) INFORMATION FOR SEQ ID NO: 4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 ammo acids
(B) TYPE: ammo acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE : NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Le u Tyr 1 5 10
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 ammo acids
(B) TYPE: ammo acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
Leu Ile Asn Cys Asn Arg Ser Ala Ile Lys Glu Ser Cys Pro 1 5 10
Lys Val Ser Phe
15
(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: ammo acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys 1 5 10
Val Thr Leu Tyr
15
(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown
(ii) MOLECULE TYFE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 :
Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys 1 5 10
Val Thr Leu Asn Cys
15
(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: ammo acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Ile Ala Met Arg
1
(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH : 4 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY : unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL : NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
Ile Lys Met Ser
1
(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 ammo acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iii) ANTI-SENSE: NO
(v) FRAGMENT TYPE: internal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
Cys Asn Thr Ser Val Ile Thr Gln Ala Cys Pro Lys Val Ser 1 5 10
Phe
15
Claims (21)
1. A molecule comprising a peptide having the amino acid sequence lysine-proline-cysteine-valine-lysine-leucinethreonine-proline-leucine-cysteine-valine (Seq. Id.No.1), wherein each cysteine residue is disulphide bridged to a further cysteine residue or is derivatised to simulate part of a disulphide bond, or functionally equivalent variants of such a peptide which mimic the immunogenic behaviour of an epitope of gρ120 of HIV env.
2. A molecule according to claim 1, wherein each cysteine residue is derivatised as a S-acetamidomethyl derivative.
3. A molecule according to claim 1, cross-linked to a further peptide sequence.
4. A molecule acording to claim 3, cross-linked as follows:
5. A molecule according to any one of claims 1 to 4, wherein the or each peptide sequence is modified by one or more individual amino acids having been substituted by amino acids having comparable properties.
6. A molecule according to any one of claims 1 to 5, wherein the or each peptide sequence is modified by one or more of the normal peptide linkages having been
substituted by isosteric replacements.
7. A molecule according to any one of claims 1 to 6, wherein the or each peptide sequence is modified by one or both pairs of disulphide-bridged cysteine residues having been substituted by a cystine analogue.
8. A molecule according to any one of claims 1 to 7, wherein the or each peptide sequence is modified by one or more of the amino acids having been replaced by a "retro-inverso" amino acid.
9. A molecule according to any one of claims 1 to 8, wherein the or each peptide sequence is modified by one or more non-essential amino acids having been deleted.
10. A molecule accordig to any one of claims 1 to 9, wherein the or each peptide sequence is modified by inclusion of one or more additional amino acids not significantly affecting function.
11. A DNA molecule coding for a peptide molecule in accordance with any one of the preceding claims.
12. A molecule according to claim 11, incorporated into a suitable expression vector.
13. A vaccine against AIDS and AIDS related conditions, comprising a molecule in accordance with any one of claims 1 to 10.
14. A vaccine according to claim 13, wherein the molecule of any one of claims 1 to 10 is linked to a carrier molecule.
15. A vaccine according to claim 13, wherein the molecule of any one of claims 1 to 10 is presented as a live vaccine.
16. A method for the prophylaxis or treatment of AIDS or related conditions, comprising administering an effective amount of a molecule in accordance with any one of claims 1 to 10.
17. A pharmaceutical composition containing, as an active ingredient, a molecule in accordance with any one of claims 1 to 10, possibly in association with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients.
18. Use of a molecule in accordance with any one of claims 1 to 10, for the preparation of a medicament for the therapy or prophylactic treatment of AIDS or related conditions.
19. A molecule that binds to the molecule of any one of claims 1 to 10, particularly an antibody, an antigen binding site of an antibody or a structural analog
thereof.
20. Use of a molecule which binds to the molecule of any one of claims 1 to 10 for therapeutic or diagnostic purposes.
AMENDED CLAIMS
[received by the International Bureau on 20 December 1993 (20.12.93)
original claims 1-20 replaced by amended claims 1-21 (4 pages) ]
1 . A molecule comprising a peptide having the amino acid sequence lysine-proline-cysteine-valine-lysine-leucinethreonine-proline-leucine-cysteine-valine ( Seq . Id . No . 1 ) , wherein each cysteine residue is disulphide bridged to a further cysteine residue or is derivatised to simulate part of a disulphide bond , or functionally equivalent variants of such a peptide which mimic the immunogenic behaviour of an epitope of gp120 of HIV env .
2. A molecule according to claim 1 , wherein each cysteine residue is derivatised as a S-acetamidomethyl derivative .
3. A molecule according to claim 1 , cross-linked to a f urther peptide sequence .
4. A molecule acording to claim 3 , cross-linked as follows :
5. A molecule according to any one of claims 1 to 4 , wherein the or each peptide sequence is modified by one or more individual amino acids having been substituted by amino acids having comparable properties .
6. A molcule according to claim 5 , comprising the
f ollowing sequences , cross-linked as indicated :
7. A molecule according to any one of claims 1 to 6, wherein the or each peptide sequence is modified by one or more of the normal peptide linkages having been
substituted by isosteric replacements.
8. A molecule according to any one of claims 1 to 7 wherein the or each peptide sequence is modified by one or both pairs of disulphide-bridged cysteine residues having been substituted by a cystine analogue.
9. A molecule according to any one of claims 1 to 8, wherein the or each peptide sequence is modified by one or more of the amino acids having been replaced by a "retro-inverso" amino acid.
10. A molecule according to any one of claims 1 to 9, wherein the or each peptide sequence is modified by one or more non-essential amino acids having been deleted.
11. A molecule according to any one of claims 1 to 10, wherein the or each peptide sequence is modified by inclusion of one or more additional amino acids not significantly affecting function.
12. A DNA molecule coding for a peptide molecule in accordance with any one of the preceding claims.
13. A molecule according to claim 12, incorporated into a suitable expression vector.
14. A vaccine against AIDS and AIDS related conditions, comprising a molecule in accordance with any one of claims 1 to 11.
15. A vaccine according to claim 14, wherein the molecule of any one of claims 1 to 11 is linked to a carrier molecule.
16. A vaccine according to claim 14, wherein the molecule of any one of claims 1 to 11 is presented as a live vaccine.
17. A method for the prophylaxis or treatment of AIDS or related conditions, comprising administering an effective amount of a molecule in accordance with any one of claims 1 to 11.
18. A pharmaceutical composition containing, as an active ingredient, a molecule in accordance with any one of claims 1 to 11, possibly in association with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients.
19. Use of a molecule in accordance with any one of claims 1 to 11, for the preparation of a medicament for the therapy or prophylactic treatment of AIDS or related conditions.
20. A molecule that binds to the molecule of any one of claims 1 to 11, particularly an antibody, an antigen binding site of an antibody or a structural analog thereof.
21. Use of a molecule which binds to the molecule of any one of claims 1 to 11 for therapeutic or diagnostic purposes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929215129A GB9215129D0 (en) | 1992-07-16 | 1992-07-16 | Development relating to human immunodeficiency viruses |
GB9215129 | 1992-07-16 | ||
PCT/GB1993/001503 WO1994002614A1 (en) | 1992-07-16 | 1993-07-16 | PEPTIDES THAT MIMIC gp120 HIV EPITOPE |
Publications (2)
Publication Number | Publication Date |
---|---|
AU4578893A true AU4578893A (en) | 1994-02-14 |
AU681591B2 AU681591B2 (en) | 1997-09-04 |
Family
ID=10718806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU45788/93A Ceased AU681591B2 (en) | 1992-07-16 | 1993-07-16 | Peptides that mimic gp120 HIV epitope |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0654080A1 (en) |
JP (1) | JPH07509237A (en) |
AU (1) | AU681591B2 (en) |
CA (1) | CA2140151A1 (en) |
GB (1) | GB9215129D0 (en) |
WO (1) | WO1994002614A1 (en) |
ZA (1) | ZA935165B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4402756A1 (en) * | 1994-01-31 | 1995-08-03 | Boehringer Mannheim Gmbh | Specific binding substances for antibodies and their use for immunoassays or vaccines |
US6911527B1 (en) | 1999-01-11 | 2005-06-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | HIV related peptides |
EP1159297A2 (en) * | 1999-01-11 | 2001-12-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Hiv related peptides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8714802D0 (en) * | 1987-06-24 | 1987-07-29 | Proteus Biotech Ltd | Synthetic polypeptides |
FR2617944B1 (en) * | 1987-07-06 | 1990-09-28 | Macc Sa | IMPROVEMENT ON EASELS |
GB8828097D0 (en) * | 1988-12-01 | 1989-01-05 | Wellcome Found | Peptides |
CA2035576A1 (en) * | 1990-02-07 | 1991-08-08 | Alexander R. Neurath | Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1 |
-
1992
- 1992-07-16 GB GB929215129A patent/GB9215129D0/en active Pending
-
1993
- 1993-07-16 EP EP93916096A patent/EP0654080A1/en not_active Withdrawn
- 1993-07-16 ZA ZA935165A patent/ZA935165B/en unknown
- 1993-07-16 CA CA002140151A patent/CA2140151A1/en not_active Abandoned
- 1993-07-16 WO PCT/GB1993/001503 patent/WO1994002614A1/en not_active Application Discontinuation
- 1993-07-16 AU AU45788/93A patent/AU681591B2/en not_active Ceased
- 1993-07-16 JP JP6504265A patent/JPH07509237A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0654080A1 (en) | 1995-05-24 |
ZA935165B (en) | 1994-03-14 |
GB9215129D0 (en) | 1992-08-26 |
WO1994002614A1 (en) | 1994-02-03 |
JPH07509237A (en) | 1995-10-12 |
AU681591B2 (en) | 1997-09-04 |
CA2140151A1 (en) | 1994-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5795955A (en) | Tandem synthetic HIV-1 peptides | |
US5013548A (en) | Production of antibodies to HIV | |
Rusche et al. | Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. | |
US5019387A (en) | Production of antibodies to HIV | |
US5589175A (en) | Peptides for induction of neutralizing antibodies against human immunodeficiency virus | |
Conley et al. | Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens | |
IE871289L (en) | Peptides, antibodies, vaccines and assay methods. | |
US5688914A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
US6080846A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
EP0762895B1 (en) | Synthetic vaccine for protection against human immunodeficiency virus infection | |
WO1993005812A1 (en) | Method to induce cytotoxic t lymphocytes specific for a broad array of hiv-1 isolates using hybrid synthetic peptides | |
AU681591B2 (en) | Peptides that mimic gp120 HIV epitope | |
AU666160B2 (en) | Compositions for eliciting cytotoxic T-lymphocyte responses against viruses | |
WO1989003813A1 (en) | Anti-retroviral agent | |
AU6515394A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
EP0498905A1 (en) | Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 | |
JP3725899B6 (en) | Multi-branched peptide constructs for use against HIV | |
JP3725899B2 (en) | Multi-branched peptide constructs for use against HIV | |
Zaghouani et al. | Immunogenicity of Synthetic Peptides Corresponding to Various Epitopes of the Human Immunodeficiency Virus Envelope Protein | |
IE990955A1 (en) | Peptides capable of being recognized by antibodies induced against retro-viruses of human immunodeficiency (HIV viruses), their uses for the diagnosis of infections due to some of these viruses and, where appropriate, for vaccination against AIDS | |
EP0547689A2 (en) | Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a T-cell stimulatory epitope |